93863-87-7

Upstream product

• 93863-44-6 (E)-6α-<2-(2,4-dichlorophenyl)ethenyl>-4β-hydroxy-2α-methoxy-3,4,5,6-tetrahydro-2H-pyran 
• 86097-37-2 Trans-(E)-6-[2-(2,4-dichlorophenyl)ethenyl]-3,4,5,6-tetrahydro-4-hydroxy-2H-pyran-2-one 
• 93922-58-8 (2S*,4R*,6S*)-(E)-6-<2-(2,4-dichlorophenyl)ethenyl>-4-hydroxy-2-methoxy-3,4,5,6-tetrahydropyran 
• 100189-68-2 (2R,4S,6R)-4-Benzyloxy-2-[(E)-2-(2,4-dichloro-phenyl)-vinyl]-6-methoxy-tetrahydro-pyran 
• 93863-41-3 methyl (E)-7-(2,4-dichlorophenyl)-5-hydroxy-3-oxo-6-heptenoate 
• 93863-43-5 methyl (E)-7-(2,4-dichlorophenyl)-3,5-dihydroxy-6-heptenoate 
• 70017-27-5 3-(2,4-Dichlorophenyl)propenal 
• 874-42-0 2,4-dichlorobenzaldeyhde 
• 100189-69-3 (2S,4R)-2-[(E)-2-(2,4-Dichloro-phenyl)-vinyl]-6-ethoxy-tetrahydro-pyran-4-ol 

Downstream Products

• 86097-37-2 Trans-(E)-6-[2-(2,4-dichlorophenyl)ethenyl]-3,4,5,6-tetrahydro-4-hydroxy-2H-pyran-2-one 
• 100295-46-3 (E)-4β-(benzyloxy)-6α-<2-(2,4-dichlorophenyl)ethenyl>-2α-methoxy-3,4,5,6-tetrahydro-2H-pyran 
• 100189-68-2 (E)-4β-(benzyloxy)-6α-<2-(2,4-dichlorophenyl)ethenyl>-2β-methoxy-3,4,5,6-tetrahydro-2H-pyran 
• 100189-69-3 (E)-6α-<2-(2,4-dichlorophenyl)ethenyl>-2α-ethoxy-4β-hydroxy-3,4,5,6-tetrahydro-2H-pyran 
• 100295-47-4 (E)-6α-<2-(2,4-dichlorophenyl)ethenyl>-2β-ethoxy-4β-hydroxy-3,4,5,6-tetrahydro-2H-pyran 
• 86097-37-2 trans-(E)-6-[2-(2,4-dichlorophenyl)ethenyl]-3,4,5,6-tetrahydro-4-hydroxy-2H-pyran-2-one 
• 93922-58-8 (2S*,4R*,6S*)-(E)-6-<2-(2,4-dichlorophenyl)ethenyl>-4-hydroxy-2-methoxy-3,4,5,6-tetrahydropyran 
• 93863-44-6 (2R*,4R*,6S*)-(E)-6-<2-(2,4-dichlorophenyl)ethenyl>-4-hydroxy-2-methoxy-3,4,5,6-tetrahydropyran 
• 93863-44-6 (2R,4S)-2-[(E)-2-(2,4-Dichloro-phenyl)-vinyl]-6-methoxy-tetrahydro-pyran-4-ol 

Relevant academic research and scientific papers

Synthesis and Utilization of the Chiral Synthon Methyl 3-O-Benzyl-2,4,6-trideoxy-6-iodo-α-D-erythro-hexopyranoside in the Synthesis of a Potent HMG-CoA Reductase Inhibitor

Synthesis of the potent HMG-CoA reductase inhibitor 1a has been achieved by utilizing the chiral synthon 2, which was prepared from methyl α-D-glucopyranoside in 12 steps (6 new).A key step in this sequence, which should have general applicability for the

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 1. Structural modification of 5-substituted 3,5-dihydroxypentanoic acids and their lactone derivatives

A series of 5-substituted 3,5-dihydroxypentanoic acids and their derivatives have been prepared and tested for inhibition of HMG-CoA reductase in vitro. In general, unless a carboxylate anion can be formed and the hydroxy groups remain unsubstituted in an erythro relationship, inhibitory activity is greatly reduced. Furthermore, only one enantiomer of the ring-opened form of lactone 6a(±) possesses the activity displayed by the racemate. Insertion of a bridging unit other than ethyl or (E)-ethenyl between the 5-carbinol moiety and an appropriate lipophilic moiety (e.g., 2,4-dichlorophenyl) attenuates activity.